<DOC>
	<DOCNO>NCT00656890</DOCNO>
	<brief_summary>The purpose study determine safety tolerability MDX-1100 regimen subject active Ulcerative colitis ( UC ) determine response rate day 57 patient administer MDX-1100 .</brief_summary>
	<brief_title>A Study MDX-1100 Subjects With Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Subjects active UC either 5ASA , corticosteroid , azathioprine ( AZA ) or/6mercaptopurine ( 6MP ) ; Mayo score 6 10 point moderate severe disease endoscopy Subjects follow medication ; 1. prednisolone â‰¤ 20 mg daily ( equivalent ) ( dose must stable least 2 week prior study drug administration ) 2 . 5ASA ( dose must stable least 4 week prior study drug administration ) 3 . AZA 6MP ( dose must stable least 3 month prior study drug administration ) 4 . Rectal steroid 5ASA ( must stable least 4 week prior study drug ) AntiTNF therapy within 8 week study drug administration Contraindication colonoscopy sigmoidoscopy Primary secondary immunodeficiency Autoimmune disease besides UC , exceptions Sjogren 's syndrome hypothyroidism History malignancy , exclude adequately treat cured basal squamous cell skin , cervical carcinoma situ Evidence acute chronic infection Clinically significant disease require medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>ulcerative colitis , rectal bleeding</keyword>
</DOC>